Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. HOWL
HOWL logo

HOWL Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Werewolf Therapeutics Inc (HOWL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
0.340
1 Day change
7.50%
52 Week Range
2.380
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

HOWL is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 available. The stock is trading weakly below the prior close, the trend remains bearish on the moving averages, insiders and hedge funds are both net sellers, and there is no recent news or financial momentum to support a long-term entry. I would not buy this now; the better call is to avoid it.

Technical Analysis

Current price is 0.33495 after a 3.57% regular-session decline, with pre-market also negative. MACD histogram is slightly positive and expanding, which suggests a short-term stabilization attempt, but RSI_6 at 44.13 is neutral and does not confirm bullish momentum. The moving average structure is bearish with SMA_200 > SMA_20 > SMA_5, showing the broader trend remains down. Price is sitting very close to pivot support at 0.333, with nearby downside levels at S1 0.29 and S2 0.264, while upside resistance sits at R1 0.375 and R2 0.402. The technical picture is weak for a long-term beginner entry.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is extremely call-heavy. The open interest put-call ratio of 0.06 and volume put-call ratio of 0.0 suggest traders are overwhelmingly positioned on the bullish side, but this looks more like speculative flow than a strong confirmation of sustainable upside, especially for a very low-priced stock. Implied volatility is extremely high at 607.67, with IV rank 63.56 and IV percentile 86.9, indicating a highly speculative setup. Call open interest (2916) far exceeds put open interest (181), but given the weak stock trend, this does not override the bearish price action.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
5

Positive Catalysts

  • No news in the recent week, so there is no clear event-driven catalyst. The only mild positive is the small positive MACD histogram expansion and the very bullish options positioning, which may indicate short-term speculative interest.

Neutral/Negative Catalysts

  • Hedge funds are selling heavily, with selling up 755.50% over the last quarter. Insiders are also selling, with selling up 194.65% over the last month. There is no recent news, no clear financial snapshot available, and no congress trading activity. The stock trend model also points to weak forward performance over the next month.

Financial Performance

No usable latest-quarter financial snapshot was provided due to an error, so there is no confirmed revenue, earnings, or growth readout to support a long-term thesis. Because the latest quarter season is unavailable, there is no evidence here of improving fundamentals.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided. Based on the available dataset, there is no visible Wall Street upgrade cycle or rising price target trend. From the pros-and-cons view, the bears currently dominate: weak trend, no news catalyst, insider and hedge fund selling. The only pro is speculative options activity, but that is not enough to justify a beginner long-term buy.

Wall Street analysts forecast HOWL stock price to rise
4 Analyst Rating
Wall Street analysts forecast HOWL stock price to rise
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 0.320
sliders
Low
1
Averages
4
High
7
Current: 0.320
sliders
Low
1
Averages
4
High
7
H.C. Wainwright
Andres Maldonado
Buy
downgrade
$10 -> $4
AI Analysis
2025-12-19
Reason
H.C. Wainwright
Andres Maldonado
Price Target
$10 -> $4
AI Analysis
2025-12-19
downgrade
Buy
Reason
H.C. Wainwright analyst Andres Maldonado lowered the firm's price target on Werewolf Therapeutics to $4 from $10 and keeps a Buy rating on the shares after the company announced a pipeline and business update. While the shares traded down on the news, the update "underscores tangible progress" toward Werewolf's primary value driver, the "creation of safer, systemically deliverable therapies," the analyst tells investors in a research note.
Wedbush
Outperform -> Neutral
downgrade
$3 -> $1
2025-12-19
Reason
Wedbush
Price Target
$3 -> $1
2025-12-19
downgrade
Outperform -> Neutral
Reason
Wedbush downgraded Werewolf Therapeutics to Neutral from Outperform with a price target of $1, down from $3.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for HOWL
Unlock Now

People Also Watch